Multimodal tumor-agnostic ctDNA analysis for minimal residual disease detection and risk stratification in ovarian cancer: results from the MITO16a/MaNGO-OV2 trial
Together, these findings establish multimodal ctDNA profiling as a sensitive, non-invasive strategy for MRD detection and longitudinal surveillance in advanced EOC, refining prognostic assessment beyond clinical and surgical factors while paving the way for precision-guided therapeutic management.
Authors
- L. Arenare
- A. Fagotti
- L. Beltrame
- E. Biagioli
- P. Chiodini
- N. Colombo
- C. Romualdi
- P. Di Gennaro
- F. Galdiero
- F. Perrone
- S. Pignata
- A. Velle
- L. Ancona
- S. Marchini
- D. Califano
- L. Mannarino
- M. Piemontese
- R. Zadro
- M. D’Incalci
- G. Tasca
- L. Paracchini
- S.C. Cecere
- D. Lorusso
Institutions
- Humanitas University (IT)
- University of Padua (IT)
- Mario Negri Institute for Pharmacological Research (IT)
- Agostino Gemelli University Polyclinic (IT)
- Istituto Oncologico Veneto (IT)
- University of Campania "Luigi Vanvitelli" (IT)
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- IRCCS Humanitas Research Hospital (IT)
- European Institute of Oncology (IT)
Publication Details
- Journal
- ESMO Open
- Published
- 2026-02-26
- DOI
- https://doi.org/10.1016/j.esmoop.2026.106087
- Citations
- 1
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 24.82